Emirates Oncology Society (EOS) shared on LinkedIn:
“Join EOS for From Risk of Recurrence to Overall Survival: Redefining Outcomes in HR+/HER2− Early Breast Cancer, an expert-led webinar exploring evolving treatment approaches and clinical outcomes in early breast cancer.
Wednesday, 4 November 2026 | Virtual
2 CME Hours
07:30 PM UAE | 03:30 PM UK | 04:30 PM Germany | 07:30 PM Oman
- International Speaker: Prof. Peter Fasching
- Moderator: Dr. Emad Dawoud
- Speakers: Dr. Hassan Jaafar, Dr. Saeed Rafii, Dr. Dina Hamza
- Endorsed by: Emirates Oncology Society
- Sponsored by: Novartis
- Managed by: Conveners.”
You can also read: Premenopausal HR+/HER2− Early Breast Cancer: Where Evidence Still Falls Short in Adjuvant Care
